IWR-1-endo

别名: endo-IWR 1, IWR-1

IWR-1-endo (endo-IWR 1, IWR-1)是一种Wnt通路抑制剂,在表达 Wnt3A 的 L-细胞中IC50为180 nM,诱导Axin2蛋白水平,并通过稳定Axin骨架破坏复合体来促进β-catenin磷酸化。

IWR-1-endo Chemical Structure

IWR-1-endo Chemical Structure

CAS: 1127442-82-3

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 975.58 现货
10mg RMB 900.38 现货
25mg RMB 2050.64 现货
100mg RMB 5151.51 现货
1g RMB 12039.3 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn

免费分装
免费预溶

客户使用Selleck的IWR-1-endo发表文献119

产品质控

批次: 纯度: 99.94%
99.94

常与IWR-1-endo一起在实验中被使用的化合物

Laduviglusib (CHIR-99021)


IWR-1-endo和CHIR99021在一定程度上支持人前列腺上皮细胞 (PrEC) 的连续细胞增殖。

Zhang C, et al. Cell Rep. 2018 Oct 16;25(3):598-610.e5.

WH-4-023


IWR-1-endo和WH-4-023以及其他细胞因子用于制备3i/LAF培养基,培养猪E10原肠胚形成前外胚层(pgEpiSC)。

Zhi M, et al. Cell Res. 2022 Apr;32(4):383-400.

SB431542


IWR-1-endo和SB431542是WNT和SMAD抑制剂,用于补充第19天的神经诱导培养基。

Popova G, et al. Elife. 2023 Jul 20;12:RP87696.

XAV-939


IWR-1-endo和XAV-939通过抑制HIV感染的PBMCs中的β-连环蛋白信号传导来消除17β-雌二醇对HIV复制的抑制。

Szotek EL, et al. Virology. 2013 Sep 1;443(2):375-83.

ICG-001


与IWR-1-endo相比,ICG-001显着减少U87细胞中核酸β-catenin的积累。

Gao L, et al. PLoS One. 2017 Aug 24;12(8):e0181346.

IWR-1-endo相关产品

相关信号通路图

Wnt/beta-catenin抑制剂选择性比较

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息
DLD1 Function assay 1 to 20 uM 24 hrs Inhibition of tankyrase in human DLD1 cells assessed as inhibition of TCF-dependent transcriptional activity at 1 to 20 uM after 24 hrs by dual luciferase reporter gene assay 24527792
DLD1 Cytotoxicity assay 1 to 20 uM 10 days Cytotoxicity against human DLD1 cells assessed as growth inhibition at 1 to 20 uM measured on day 10 by crystal violet staining 24527792
HT29 Function assay 25 uM 24 hrs Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity at 25 uM after 24 hrs by dual luciferase reporter gene assay relative to control 24950489
HT29 Function assay 25 uM 24 hrs Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity at 25 uM after 24 hrs by dual luciferase reporter gene assay relative to control in presence of GSK-3beta inhibitor LiCl 24950489
HT29 Function assay 25 uM 24 hrs Inhibition of Wnt/beta-catenin signaling in human HT29 cells assessed as increase in axin2 mRNA expression at 25 uM after 24 hrs by quantitative real-time PCR assay 24950489
DLD1 Function assay 10 uM Induction of Axin2 in human DLD1 cells overexpressing IWR-IS assessed as decrease in Wnt pathway activity at 10 uM by STF reporter assay method 19125156
HT29 Function assay 24 hrs Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control, IC50 = 24.4 μM. 24950489
L-Wnt-STF Function assay 24 hrs Inhibition of TNKS-1 in mouse L-Wnt-STF cells assessed as disruption of Wnt signaling after 24 hrs by luciferase reporter gene assay, IC50 = 0.131 μM. 24527792
L-Wnt-STF Function assay 24 hrs Inhibition of TNKS-2 in mouse L-Wnt-STF cells assessed as disruption of Wnt signaling after 24 hrs by luciferase reporter gene assay, IC50 = 0.056 μM. 24527792
SW480 Function assay 40 to 48 hrs Inhibition of tankyrase in human SW480 cells assessed as degradation of beta catenin after 40 to 48 hrs, IC50 = 0.25 μM. 23701517
SW480 Function assay 24 hrs Inhibition of tankyrase in human SW480 cells assessed as accumulation of axin2 after 24 hrs by Hoechst dye-based method, EC50 = 2.5 μM. 23701517
BL21 (DE3) Function assay 90 mins Activity of N-terminus hexaHis-tagged human TNSK2 expressed in Escherichia coli BL21 (DE3) cells using biotinylated NAD+ as substrate after 90 mins by Western blot analysis, EC50 = 0.2 μM. 22233320
DLD1 Function assay 2 hrs Induction of Axin2 stabilization in human DLD1 cells assessed as decreased transcription of Axin2 after 2 hrs by RT-PCR method 19125156
HEK293T Function assay Inhibition of beta-casein-dependent canonical Wnt3 pathway in human HEK293T cells by luciferase reporter gene assay, IC50 = 0.026 μM. 22191557
HEK293 Function assay Displacement of IWR-PB from Axin2 in HEK293 cells by Western blot method 19125156
DLD1 Function assay Inhibition of Axin2 protein degradation in human DLD1 cells by Western blot analysis 19125156
DLD1 Function assay Induction of Axin2 accumulation in human DLD1 cells assessed as increase in Thr41 phosphorylated beta-casein levels by Western blot analysis 19125156
DLD1 Function assay Induction of Axin2 accumulation in human DLD1 cells assessed as increase in Ser37 phosphorylated beta-casein levels by Western blot analysis 19125156
DLD1 Function assay Decrease in beta-casein accumulation in human DLD1 cells expressing in APC mutant 19125156
DLD1 Function assay Induction of Axin2 accumulation in human DLD1 cells assessed as decrease in free beta-casein levels by Western blot analysis 19125156
DLD1 Function assay Induction of Axin2 stabilization in human DLD1 cells assessed as inhibition of Wnt/beta-casein pathway 19125156
DLD1 Function assay Induction of Axin2 accumulation in human DLD1 cells assessed as increase in Ser33 phosphorylated beta-casein levels by Western blot analysis 19125156
DLD1 Function assay Induction of Axin2 accumulation in human DLD1 cells by Western blot analysis 19125156
点击查看更多细胞系数据

生物活性

产品描述 IWR-1-endo (endo-IWR 1, IWR-1)是一种Wnt通路抑制剂,在表达 Wnt3A 的 L-细胞中IC50为180 nM,诱导Axin2蛋白水平,并通过稳定Axin骨架破坏复合体来促进β-catenin磷酸化。
靶点
Wnt [1]
(L-cells expressing Wnt3A)
180 nM
体外研究(In Vitro)
体外研究活性

IWR-1 和XAV939作为Wnt通路的可逆抑制剂,在体内外具有相似的药理作用,IWR-1通过与Axin相互作用而发挥效果,而XAV939直接与TNKS结合。[1]

实验图片 检测方法 检测指标 实验图片 PMID
Western blot Survivin p-Akt / Akt E-cadherin / N-cadherin / Snail / Vimentin 26450645

化学信息&溶解度

分子量 409.44 分子式

C25H19N3O3

CAS号 1127442-82-3 SDF --
Smiles C1C2C=CC1C3C2C(=O)N(C3=O)C4=CC=C(C=C4)C(=O)NC5=CC=CC6=C5N=CC=C6
储存条件(自收到货起)

体外溶解度
批次:

DMSO : 82 mg/mL ( (200.27 mM); DMSO吸湿会降低化合物溶解度,请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次:

现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy IWR-1-endo | IWR-1-endo supplier | purchase IWR-1-endo | IWR-1-endo cost | IWR-1-endo manufacturer | order IWR-1-endo | IWR-1-endo distributor
在线咨询
联系我们